These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35638227)

  • 21. People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?
    Bartalucci C; Baldi F; Ricci E; Orofino G; Menzaghi B; Ferrara S; Pellicano' GF; Squillace N; Sarchi E; Pontali E; Cenderello G; Bargiacchi O; Piccica M; Carleo MA; Cascio A; De Socio GV; Bonfanti P; Di Biagio A
    AIDS; 2024 Mar; 38(3):430-434. PubMed ID: 38300162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A HIV Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.
    Valin N; Lambert-Niclot S; Torres E; Meynard JL; Périllaud-Dubois C; Morand-Joubert L; Lacombe K
    Clin Infect Dis; 2024 Jul; 79(1):196-197. PubMed ID: 38513236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
    Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV.
    Qazzaz H; Parganas C; Cory TJ
    Expert Opin Pharmacother; 2022 Sep; 23(13):1485-1495. PubMed ID: 36124818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.
    van Welzen BJ; Van Lelyveld SFL; Ter Beest G; Gisolf JH; Geerlings SE; Prins JM; Van Twillert G; Van Nieuwkoop C; Van der Valk M; Burger D; Wensing AMJ
    Clin Infect Dis; 2024 Jul; 79(1):189-195. PubMed ID: 38207125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.
    Zeuli JD; Rivera CG; Smith BL; Otto A; Temesgen Z
    Drugs Today (Barc); 2022 Dec; 58(12):555-576. PubMed ID: 36651065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
    Cossu MV; Cattaneo D; Moschese D; Giacomelli A; Soloperto S; D'Avolio A; Antinori S; Gori A; Rizzardini G; Gervasoni C
    J Antimicrob Chemother; 2024 May; 79(5):1126-1132. PubMed ID: 38530862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area.
    Nguyen NM; Kavanagh R; Gozar M; Cabral D; Goetz H; Cha A; McGowan JP; Pao ML
    AIDS Patient Care STDS; 2024 Mar; 38(3):115-122. PubMed ID: 38471090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
    Chounta V; Snedecor SJ; Wu S; Van de Velde N
    BMC Infect Dis; 2022 May; 22(1):428. PubMed ID: 35508986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions.
    Rusconi S; Santoro MM; Capetti AF; Gianotti N; Zazzi M
    Int J Antimicrob Agents; 2022 Sep; 60(3):106627. PubMed ID: 35760225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience.
    Castelli A; Lanzafame M; Morra M; Bertoldi M; Delama A; Fait D; Vento S
    AIDS Res Hum Retroviruses; 2024 May; 40(5):283-285. PubMed ID: 37776179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
    Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
    J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
    Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries.
    Steegen K; Chandiwana N; Sokhela S; Venter WDF; Hans L
    AIDS; 2023 May; 37(6):1009-1011. PubMed ID: 36779485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
    Czarnogorski M; Benn P; McCoig C; Nwafor T; Griffith S; Sutton K; Harrington C; Saggu P; Yague I; Williams W; Español CM; Goodchild J; Fricker J; Patel P; D'Amico R
    J Acquir Immune Defic Syndr; 2022 Oct; 91(2):157-161. PubMed ID: 36094481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
    Gutner CA; Hocqueloux L; Jonsson-Oldenbüttel C; Vandekerckhove L; van Welzen BJ; Slama L; Crusells-Canales M; Sierra JO; DeMoor R; Scherzer J; Ait-Khaled M; Bontempo G; Gill M; Patel N; D'Amico R; Hove K; Baugh B; Barnes N; Hadi M; Low EL; Anand SB; Hamilton A; Garges HP; Czarnogorski M
    J Int AIDS Soc; 2024 Jul; 27(7):e26243. PubMed ID: 38978405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine.
    Rubenstein E; Diemer M; Goldwirt L; Lascoux-Combe C; Chaix ML; Rami A; Ponscarme D; Lafaurie M; Denis B; De Castro N; Gras J; Liegeon G; Sellier PO; Deville L; Chevret S; Delaugerre C; Molina JM
    AIDS; 2024 Jul; 38(8):1267-1269. PubMed ID: 38814715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel.
    Sax PE; Thompson MA; Saag MS;
    JAMA; 2024 Mar; 331(12):1060-1061. PubMed ID: 38427337
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
    Letendre SL; Mills A; Hagins D; Swindells S; Felizarta F; Devente J; Bettacchi C; Lou Y; Ford S; Sutton K; Shaik JS; Crauwels H; D'Amico R; Patel P
    J Antimicrob Chemother; 2020 Mar; 75(3):648-655. PubMed ID: 31873746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.